Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Trail interacts redundantly with nitric oxide in rat astrocytes: potential contribution to neurodegenerative processes.

Cantarella G, Lempereur L, D'Alcamo MA, Risuglia N, Cardile V, Pennisi G, Scoto GM, Bernardini R.

J Neuroimmunol. 2007 Jan;182(1-2):41-7. Epub 2006 Oct 24.

PMID:
17067687
2.

Hydrogen peroxide enhances TRAIL-induced cell death through up-regulation of DR5 in human astrocytic cells.

Kwon D, Choi K, Choi C, Benveniste EN.

Biochem Biophys Res Commun. 2008 Aug 8;372(4):870-4. doi: 10.1016/j.bbrc.2008.05.148. Epub 2008 Jun 4.

PMID:
18534188
3.
4.

Expression of TRAIL and the death receptors DR4 and DR5 correlates with progression of degeneration in human intervertebral disks.

Bertram H, Nerlich A, Omlor G, Geiger F, Zimmermann G, Fellenberg J.

Mod Pathol. 2009 Jul;22(7):895-905. doi: 10.1038/modpathol.2009.39. Epub 2009 Mar 20.

5.

TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.

Zhang Y, Zhang B.

Mol Cancer Res. 2008 Dec;6(12):1861-71. doi: 10.1158/1541-7786.MCR-08-0313.

6.

PRMT5, a novel TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis via nuclear factor-kappaB activation.

Tanaka H, Hoshikawa Y, Oh-hara T, Koike S, Naito M, Noda T, Arai H, Tsuruo T, Fujita N.

Mol Cancer Res. 2009 Apr;7(4):557-69. doi: 10.1158/1541-7786.MCR-08-0197.

7.

Increased glutathione biosynthesis by Nrf2 activation in astrocytes prevents p75NTR-dependent motor neuron apoptosis.

Vargas MR, Pehar M, Cassina P, Beckman JS, Barbeito L.

J Neurochem. 2006 May;97(3):687-96. Epub 2006 Mar 8.

8.

Essential role of mitogen-activated protein kinase pathways in protease activated receptor 2-mediated nitric-oxide production from rat primary astrocytes.

Park GH, Jeon SJ, Ryu JR, Choi MS, Han SH, Yang SI, Ryu JH, Cheong JH, Shin CY, Ko KH.

Nitric Oxide. 2009 Sep;21(2):110-9. doi: 10.1016/j.niox.2009.05.007. Epub 2009 Jun 13.

PMID:
19527794
9.

Nitric oxide-induced apoptosis in cultured rat astrocytes: protection by edaravone, a radical scavenger.

Kawasaki T, Kitao T, Nakagawa K, Fujisaki H, Takegawa Y, Koda K, Ago Y, Baba A, Matsuda T.

Glia. 2007 Oct;55(13):1325-33.

PMID:
17626263
10.

Pharmacological inhibition of Bcl-2 family members reactivates TRAIL-induced apoptosis in malignant glioma.

Hetschko H, Voss V, Horn S, Seifert V, Prehn JH, Kögel D.

J Neurooncol. 2008 Feb;86(3):265-72. Epub 2007 Oct 9.

PMID:
17924059
11.

Silibinin sensitizes human glioma cells to TRAIL-mediated apoptosis via DR5 up-regulation and down-regulation of c-FLIP and survivin.

Son YG, Kim EH, Kim JY, Kim SU, Kwon TK, Yoon AR, Yun CO, Choi KS.

Cancer Res. 2007 Sep 1;67(17):8274-84.

12.

Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.

Ortiz-Ferrón G, Yerbes R, Eramo A, López-Pérez AI, De Maria R, López-Rivas A.

Cell Res. 2008 Jun;18(6):664-76. doi: 10.1038/cr.2008.54.

13.

Upregulation of DR5 by proteasome inhibitors potently sensitizes glioma cells to TRAIL-induced apoptosis.

Hetschko H, Voss V, Seifert V, Prehn JH, Kögel D.

FEBS J. 2008 Apr;275(8):1925-36. doi: 10.1111/j.1742-4658.2008.06351.x. Epub 2008 Mar 13.

15.
16.

Andrographolide sensitizes cancer cells to TRAIL-induced apoptosis via p53-mediated death receptor 4 up-regulation.

Zhou J, Lu GD, Ong CS, Ong CN, Shen HM.

Mol Cancer Ther. 2008 Jul;7(7):2170-80. doi: 10.1158/1535-7163.MCT-08-0071.

17.

Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1.

Huerta-Yepez S, Vega M, Escoto-Chavez SE, Murdock B, Sakai T, Baritaki S, Bonavida B.

Nitric Oxide. 2009 Feb;20(1):39-52. doi: 10.1016/j.niox.2008.08.001. Epub 2008 Aug 22.

PMID:
18778787
18.

Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response.

Jiang CC, Chen LH, Gillespie S, Kiejda KA, Mhaidat N, Wang YF, Thorne R, Zhang XD, Hersey P.

Cancer Res. 2007 Jun 15;67(12):5880-8.

19.

TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.

Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA.

Mol Cancer Ther. 2007 Jul;6(7):2103-12.

20.
Items per page

Supplemental Content

Write to the Help Desk